AMR Alliance Japan (Secretariat: Health and Global Policy Institute) held a meeting to discuss its FY2024 plans among Alliance members.

AMR Alliance Japan, as an independent platform for multisector discussion with the mission of contributing to the improvement of public health by promoting measures on AMR, will continue to work with Alliance members and partner organizations to deepen policy debate around AMR.

[Overview]

• Date & time: Thursday, February 1, 2024
• Format: Online (Zoom meeting)
• Organizer: AMR Alliance Japan (Secretariat: HGPI)

 

■Discussion

Participants (Titles omitted; in no particular order)

Kazuyuki Akai (Market Shaping Director, Nippon Becton Dickinson Company Ltd.)
Kyoko Ama (Representative, the Children and Healthcare Project / Fellow, Health and Global Policy Institute)
Kazunobu Ouchi (Auditor, Japanese Society for Pediatric Infectious Diseases / Specially Appointed Professor, Department of Medical Welfare for Children, Faculty of Health and Welfare, Kawasaki University of Medical Welfare / Specially Appointed Manager, Kawasaki Medical School General Medical Center / Professor emeritus, Kawasaki Medical School)
Shogo Osaki (Manager, Community Medical Division, Health and Welfare Bureau, Himeji City)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K.K.)
Katsunori Kanazawa (Infectious Diseases Officer, Medical Information, Sumitomo Pharma Co., Ltd.)
Satoshi Kamayachi (Executive Board Member, Japan Medical Association)
Yoko Kayama (Japan Medicine Development Leader, Japan Medical and Development, GlaxsoSmithKline K.K.)
Katsuyoshi Kii (Director, Public&Government Affairs, Biomerieux Japan Ltd.)
Takashi Kitahara (Chairman, Japan Pharmaceutical Association / Professor, Department of Clinical Pharmacology, Yamaguchi University)
Ryoko Kibe (Japanese Society of Antimicrobials for Animals / Assistant Professor, Nippon Veterinary and Life Science University）
Takeshi Kobayashi (Director, Market Development Headquarters, Shimadzu Diagnostics Corporation)
Hayato Shishido (Group Manager, Clinical Diagnostics Sales Department, Shimadzu Diagnostics Corporation)
Mitsuru Sugawara (President, Japanese Society of Therapeutic Drug Monitoring / Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
Yoshisaburo Takahashi (General Manager, Vaccine/Infections Dept., Meiji Seika Pharma Co., Ltd.)
Kazuhiro Tateda (Chairman, the Joint Review Committee of Seven Academic Societies for the Promotion of Infectious Disease Therapy and Drug Discovery / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Masaya Tamae (Executive Officer and Associate General Manager, Corporate Planning & Strategy Division, Meiji Seika Pharma Co.,Ltd)
Yasunori Tawaragi (AMR Advocacy Task Force Leader, Japan Pharmaceutical Manufacturers Association)
Mitsuaki Nagasawa (Vice President, Japanese Association of Medical Technologists)
Hajime Hashiba (Managing Director, Japan Pharmaceutical Association)
Naoki Hasegawa (President, Japanese Association for Infectious Diseases)
Junichi Hirayama (MA Specialist, Medical Affairs, Biomerieux Japan Ltd.)
Megumi Maruyama (Global Health Officer, Sumitomo Pharma Co., Ltd.)
Akihiro Morimoto (Sr. Manager, Policy & Public Affairs, Pfizer Japan Inc.)
Akira Yuasa (Sr. Manager, Health & Value, Pfizer Japan Inc.)
Hiroshi Yotsuyanagi (Auditor, Japanese Society for Infection Prevention and Control / Director, IMUST Hospital, Institute of Medical Science, University of Tokyo)

Moderator:
Yui Kohno (Manager, Health and Global Policy Institute)